Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
26.50
+1.41 (5.62%)
At close: Mar 6, 2026, 4:00 PM EST
26.50
0.00 (0.00%)
After-hours: Mar 6, 2026, 6:30 PM EST
Evommune Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | 13 | 7 | 5 |
| Revenue Growth (YoY) | 85.71% | 40.00% | - |
| Gross Profit | 13 | 7 | 5 |
| Selling, General & Admin | 20.03 | 12.77 | 10.85 |
| Research & Development | 74.04 | 64.24 | 32 |
| Operating Expenses | 94.07 | 77.01 | 42.85 |
| Operating Income | -81.07 | -70.01 | -37.85 |
| Interest Expense | - | -0.03 | -0.06 |
| Interest & Investment Income | 3.32 | 3.24 | 3.86 |
| Other Non Operating Income (Expenses) | 8.88 | -0 | -0 |
| Pretax Income | -68.87 | -66.81 | -34.05 |
| Net Income | -68.87 | -66.81 | -34.05 |
| Preferred Dividends & Other Adjustments | - | 1.5 | - |
| Net Income to Common | -68.87 | -68.31 | -34.05 |
| Shares Outstanding (Basic) | 6 | 2 | 1 |
| Shares Outstanding (Diluted) | 6 | 2 | 1 |
| Shares Change (YoY) | 306.85% | 20.35% | - |
| EPS (Basic) | -11.22 | -45.29 | -27.17 |
| EPS (Diluted) | -11.22 | -45.29 | -27.17 |
| Free Cash Flow | -76.68 | -58.28 | -30.09 |
| Free Cash Flow Per Share | -12.49 | -38.64 | -24.01 |
| Gross Margin | 100.00% | 100.00% | 100.00% |
| Operating Margin | -623.62% | -1000.19% | -757.00% |
| Profit Margin | -529.77% | -975.83% | -681.06% |
| Free Cash Flow Margin | -589.82% | -832.61% | -601.76% |
| EBITDA | -79.68 | -68.73 | -36.85 |
| D&A For EBITDA | 1.39 | 1.29 | 1 |
| EBIT | -81.07 | -70.01 | -37.85 |
| Revenue as Reported | 13 | 7 | 5 |
Source: S&P Capital IQ. Standard template.
Financial Sources.